伐昔洛韦不同用药方案治疗复发性生殖器疱疹的疗效观察  

Therapeutic effect of different dosages of valaciclovir on the treatment of recurrent genital herpes

作　　者：周敏 陈艳[2] 

机构地区：[1]慈溪市第三人民医院皮肤科,浙江宁波315300 [2]宁波市第二医院皮肤科,浙江宁波315000

出　　处：《中国性科学》2014年第2期55-57,共3页Chinese Journal of Human Sexuality

摘　　要：目的:探讨分析伐昔洛韦不同用药方案治疗复发性生殖器疱疹的临床疗效。方法:选取我院于2011年2月至2013年4月收治的152例复发性生殖器疱疹的患者,将所有患者按随机数法分为实验组与对照组,两组均为76例。所有患者均服用伐昔洛韦进行治疗,对照组连续服用7d,2次/d,300mg/次,实验组连续服用5d,2次/d,500mg/次。对比分析两组的临床疗效及治疗过程中不良反应的发生情况。结果:实验组与对照组第1d、第3d、第5d、第7d基于积分的有效率的差异比较无统计学意义(P>0.05);实验组治疗第1d HSV培养阳性率要明显低于对照组(P<0.05),两组第2d HSV培养阳性率的差异比较无统计学意义(P>0.05);实验组与对照组治疗过程中不良反应发生率的差异比较无统计学意义(P>0.05)。结论:增加伐昔洛韦的单次用量治疗复发性生殖器疱疹效果显著,单纯疱疹病毒在皮损局部的存在时间明显缩短,且不良反应的发生率未明显提升。Objectives： To study the effect of different dosages of valaciclovir on the treatment of recurrent genital herpes. Methods： One hudred and fifty two patients with recurrent genital herpes who came to our hospital from February, 2011 - April 2013 were randomly divided into the experimental group （valaciclovir 500mg twice daily orally for 5 days） and the control group （ valaciclovir 300rag twice daily orally for 7 days）. There were 76 cases in each group. Clinical effect and side effect of the two groups were compared. Results： No significant difference was observed in the decrease of symptom score or response rate on 1st , 2nd, 3rd and 7th day after the treatment （ P 〉 0.05 ）. The positive rate of HSV culture of the experimental group was statistically lower than that of the control group on ld after the treatment （P 〈 0. 05）, while the difference of positive rates of HSV culture between the two groups was not statistically significant （ P 〉 0. 05 ） on 2d after the treatment. The difference of side effect occurrence in the two groups was not statistically significant （ P 〉 0.05 ）. Conclusion ： The increase in valaciclovir dosage has a significant effect on the treatment of recurrent genital herpes. The increased dosage can shorten the retention of herpes virus in local lesions and can produce few side effects.

关 键 词：复发性生殖器疱疹 伐昔洛韦 不同用药方案 临床疗效 

分 类 号：R752.1[医药卫生—皮肤病学与性病学]